New immunotherapy ‘highly effective’ against hepatitis B
Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.
by ·
Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world.
by · Published April 12, 2021
by · Published April 28, 2021
by · Published April 18, 2021